The Institute of Chemical Technology (ICT), Mumbai, and India’s Translational Research Initiative (ITRI) have signed a formal Expression of Interest (EOI) to jointly catalyse the creation of the Mumbai Biocluster—a state-of-the-art, eight-storey hub dedicated to translational biopharmaceutical research, training, and manufacturing.
Bridging the Gap
The Mumbai Biocluster directly tackles one of India’s most pressing challenges in the innovation ecosystem—closing the gap between early-stage discovery and large-scale clinical or commercial translation. By enabling this crucial leap, the facility aims to accelerate the journey of breakthrough therapies from lab to market.
Catalytic Support to Drive National R&D Output
With ITRI’s catalytic support, the Mumbai Biocluster will deliver a multiplier effect on India’s R&D landscape, enabling faster translation of biomedical innovations. Key planned features include:
*GMP-ready biologics pilot plant for process scale-up
*Specialised centres for rare diseases, process development, synthetic biology, and AI-driven drug discovery
*Shared analytical, formulation, and quality platforms to reduce duplication and costs
*Advanced training and upskilling modules to strengthen India’s biopharma workforce
Reducing Capital Barriers and Accelerating Scale-Up
The facility will operate on a service-driven business model, providing high-end shared instrumentation to lower capital costs for innovators. It will also offer infrastructure for technology validation, scale-up, and cross-disciplinary collaboration, fostering partnerships across departments and institutions.
Building Capacity and Entrepreneurial Pathways
As reported by biospectrumindia.com, beyond infrastructure, the Mumbai Biocluster will drive workforce development and entrepreneurship, creating pathways for students, researchers, and start-ups to engage in translational research and contribute to India’s biopharma growth story.
